The Chancellor’s Spending Review, delivered on 11 June, outlines major investment priorities for 2026–2030 with big implications for life sciences. From UKRI to the NHS, find out what it means for the sector and what to expect from the upcoming Industrial Strategy. Watch this webinar and listen in on BIA experts as they unpack the headlines.
BIA has released a new explainer highlighting why the UK is well-positioned to lead in functional genomics, thanks to its unparalleled research capacity and exceptional talent pool.
This report from the BIA delves into the strategic importance of functional genomics, highlighting its potential to drive innovation across diverse applications, particularly in healthcare.
In this blog Richard Turner, the new vice chair of FTAC, examines the UK's overhauled R&D tax regime, which provides competitive incentives and a stable fiscal framework.
WHO members adopted the pandemic preparedness accord as an international treaty at the World Health Assembly. In this blog, Senior Policy and Public Affairs Manager Linda Bedenik looks at what the agreement means for life sciences.
New studies presented at the American Thoracic Society (ATS) Conference this week validate e-Lung as an accurate tool to identify progressive pulmonary fibrosis.
In 2035, we envision a UK biotech sector with a stronger long-term capital base supporting both early—and later-stage firms. To make Vision 2035 a reality, we, as a sector, must focus on areas that will have the greatest impact. Read the report to find out what those are!
Welcome to our new-look quarterly report, where the BIA team share examples of the influence we are delivering for members on government policy and the global life sciences ecosystem.
In this blog, Dr Emma Lawrence, Head of data tech policy and public affairs at BIA, writes about the UK government's recent £600 million initiative to launch a Health Data Research Service which aims to revolutionize access to NHS data and tackle longstanding governance and technical hurdles.
The Prime Minister’s announcement of a national health data research service is welcome news for the UK life science sector. We have a wealth of small innovative companies in the UK, working in an ecosystem, that are developing solutions to help us prevent, detect and treat disease better than before.
Can “good bacteria” be used to maintain good health as we grow older? Scottish biotech company NCIMB has teamed up with the Rowett Institute to address this question.
Prof Rory Johnson, Associate Professor, University College Dublin and Dr Shalini Andersson, Vice President Nucleic Acid Therapeutics, AstraZeneca, will lead this year’s event, focussed on ‘drugging the undruggable’.
